March 09, 2020
Celgene Corp. has been slapped with a lawsuit from health insurance giant UnitedHealthcare Services Inc. over claims that the company stopped generic competitors from selling equivalents to Celgene's brand-name cancer drugs, Thalomid and Revlimid.